https://www.selleckchem.com/pr....oducts/lirafugratini
Treatment with the iNOS inhibitor 1400W or mutation of GAPDH S-nitrosation sites alleviated apoptosis of C2C12 cells, further demonstrating that GAPDH S-nitrosation in aging contributes to sarcopenia. Taken together, these findings reveal a new cellular mechanism underlying age-related sarcopenia, and the demonstration of muscle loss mediated by iNOS-induced GAPDH S-nitrosation suggests a potential therapeutic strategy for sarcopenia. Despite the fact that bevacizumab (Bev) has been approved to treat recurrent glioblastoma, patie
Like
Comment
Share
